Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer

被引:87
作者
Birkholz, K. [1 ]
Hombach, A. [2 ]
Krug, C. [1 ]
Reuter, S. [1 ]
Kershaw, M. [3 ]
Kaempgen, E. [1 ]
Schuler, G. [1 ]
Abken, H. [2 ]
Schaft, N. [1 ]
Doerrie, J. [1 ]
机构
[1] Univ Hosp Erlangen, Dept Dermatol, D-91052 Erlangen, Bavaria, Germany
[2] Univ Cologne, CMMC, Cologne, Germany
[3] Peter MacCallum Canc Ctr, Canc Immunol Sect, Melbourne, Vic, Australia
关键词
RNA transfection; retroviral gene transfer; chimeric TCR; immunoreceptor; DENDRITIC CELLS; GENE-THERAPY; HUMAN-BREAST; CLASS-I; RECEPTOR; LYMPHOCYTES; EXPRESSION; ELECTROPORATION; MELANOMA; TCR;
D O I
10.1038/gt.2008.189
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human T lymphocytes can be redirected with a new defined specificity by expression of a chimeric T-cell receptor (immunoreceptor) for the use in adoptive immunotherapy of cancer. Whereas standard procedures use retroviral gene transduction to constitutively express immunoreceptors in T cells, we here explored for the first time mRNA electroporation to achieve transient immunoreceptor expression, and thereby minimizing the risk of persistence of potential autoaggression. CD4(+) and CD8(+) T cells were efficiently transfected with immunoreceptors specific for ErbB2 and CEA. The immunoreceptor expression was transient with half-maximal expression at day 2 and no detectable immunoreceptor expression at day 9 after electroporation. Immunoreceptor-transfected T cells were specifically activated upon coincubation with ErbB2(+) and CEA(+) tumor cells, respectively, resulting in secretion of interferon-gamma (IFN gamma), interleukin-2 (IL-2), and tumor necrosis factor-alpha (TNF alpha). Furthermore, immunoreceptor-transfected CD8(+) T cells specifically lysed ErbB2(+) and CEA(+) tumor cells, respectively. The RNA-transfected T cells retained their cytotoxic function after 2 days of activation and exhibited cytolytic activities like retrovirally transduced T cells. RNA electroporation of T cells thereby provides a versatile tool for transient immunoreceptor expression, which may be of advantage in avoiding the persistence of unintended auto-aggression. Gene Therapy (2009) 16, 596-604; doi: 10.1038/gt.2008.189; published online 22 January 2009
引用
收藏
页码:596 / 604
页数:9
相关论文
共 46 条
[1]  
[Anonymous], 2006, J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol, DOI DOI 10.1200/JCO.2006.05.9964
[2]  
Bolhuis Reinder L. H., 2000, P423
[3]   Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA [J].
Bonehill, Aude ;
Tuyaerts, Sandra ;
Van Nuffel, An Mt ;
Heirman, Carlo ;
Bos, Tomas J. ;
Fostier, Karel ;
Neyns, Bart ;
Thielemans, Kris .
MOLECULAR THERAPY, 2008, 16 (06) :1170-1180
[4]   Safety of retroviral gene marking with a truncated NGF receptor [J].
Bonini, C ;
Grez, M ;
Traversari, C ;
Ciceri, F ;
Marktel, S ;
Ferrari, G ;
Dinauer, M ;
Sadat, M ;
Aiuti, A ;
Deola, S ;
Radrizzani, M ;
Hagenbeek, A ;
Apperley, J ;
Ebeling, S ;
Martens, A ;
Kolb, HJ ;
Weber, M ;
Lotti, F ;
Grande, A ;
Weissinger, E ;
Bueren, JA ;
Lamana, M ;
Falkenburg, JHF ;
Heemskerk, MHM ;
Austin, T ;
Kornblau, S ;
Marini, F ;
Benati, C ;
Magnani, Z ;
Cazzaniga, S ;
Toma, S ;
Gallo-Stampino, C ;
Introna, M ;
Slavin, S ;
Greenberg, PD ;
Bregni, M ;
Mavilio, F ;
Bordignon, C .
NATURE MEDICINE, 2003, 9 (04) :367-369
[5]   Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells [J].
Breckpot, K ;
Heirman, C ;
Neyns, B ;
Thielemans, K .
JOURNAL OF GENE MEDICINE, 2004, 6 (11) :1175-1188
[6]   Gene therapy for SCID - a complication after remarkable progress [J].
Buckley, RH .
LANCET, 2002, 360 (9341) :1185-1186
[7]  
Butterfield LH, 2003, CLIN CANCER RES, V9, P998
[8]   The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma [J].
Cheadle, Eleanor J. ;
Gilham, David E. ;
Hawkins, Robert E. .
BRITISH JOURNAL OF HAEMATOLOGY, 2008, 142 (01) :65-68
[9]  
Clay TM, 1999, J IMMUNOL, V163, P507
[10]  
Cooper LJN, 2006, CYTOTHERAPY, V8, P105, DOI 10.1080/14653240600620176